Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;89(3):598-603.
doi: 10.1002/ana.25987. Epub 2020 Dec 28.

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19

Marcos Fragiel  1 , Òscar Miró  2 , Pere Llorens  3 , Sònia Jiménez  2 , Pascual Piñera  4 , Guillermo Burillo  5 , Alfonso Martín  6 , Francisco J Martín-Sánchez  1 , Eric J García-Lamberechts  1 , Javier Jacob  7 , Aitor Alquézar-Arbé  8 , Ricardo Juárez  9 , Blas Jiménez  10 , Rigoberto Del Rio  11 , Miriam Mateo Roca  8 , Arturo H García  12 , Nieves López Laguna  13 , María P Lopez Diez  14 , Jorge Pedraza García  15 , Amparo Fernández de Simón Almela  16 , Juan J Lopez Diaz  17 , Patricia Eiroa Hernández  18 , Noemí Ruiz de Lobera  19 , Jesús Porta-Etessam  20 , Cristina Fernández Pérez  21 , Elpidio Calvo  22 , Juan González Del Castillo  1 ; SIESTA (Spanish Investigators in Emergency Situations Team) network
Affiliations
Free article

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19

Marcos Fragiel et al. Ann Neurol. 2021 Mar.
Free article

Abstract

We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15‰) than non-COVID (0.02‰) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2021;89:598-603.

PubMed Disclaimer

Comment in

References

    1. Zhao H, Shen D, Zhou H, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383-384.
    1. Sedaghat Z, Karimi N. Guillain-Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 2020;76:233-235.
    1. Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020;382:2574-2576.
    1. Caress J, Castoro RJ, Simmons Z, et al. COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 2020;62:485-491.
    1. Ottaviani D, Boso F, Tranquillini E, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci 2020;41:1351-1354.

MeSH terms

Substances